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Introduction: Recently extracellular vesicles (exosomes, microparticles also referred to as microvesicles and apo-
ptotic bodies) have attracted substantial interest as potential biomarkers and therapeutic vehicles. However,
analysis of microparticles in biological ﬂuids is confounded by many factors such as the activation of cells in
the blood collection tube that leads to in vitro vesiculation. In this studywe aimed at identifying an anticoagulant
that prevents in vitro vesiculation in blood plasma samples.
Materials and Methods:We compared the levels of platelet microparticles and non-platelet-derived microparti-
cles in platelet-free plasma samples of healthy donors. Platelet-free plasma samples were isolated using different
anticoagulant tubes, and were analyzed by ﬂow cytometry and Zymuphen assay. The extent of in vitro vesicula-
tion was compared in citrate and acid-citrate-dextrose (ACD) tubes.
Results: Agitation and storage of blood samples at 37 °C for 1 hour induced a strong release of both platelet mi-
croparticles and non-platelet-derivedmicroparticles. Strikingly, in vitro vesiculation related to blood sample han-
dling and storage was prevented in samples in ACD tubes. Importantly, microparticle levels elevated in vivo
remained detectable in ACD tubes.
Conclusions:We propose the general use of the ACD tube instead of other conventional anticoagulant tubes for
the assessment of plasma microparticles since it gives a more realistic picture of the in vivo levels of circulating
microparticles and does not interfere with downstream protein or RNA analyses.
© 2013 Elsevier Ltd. All rights reserved.
Introduction
Extracellular vesicles (EVs) are membrane surrounded structures of
various sizes (30-5000 nm) that have received signiﬁcant attention re-
cently [1]. EVs may be classiﬁed on the basis of their biogenesis, diame-
ter and membrane markers. The two best characterized types of EVs
include exosomes of endosomal origin and plasma membrane-derived
microparticles (MPs) (recently often referred to also as microvesicles
or ectosomes in the literature) [1]. EVs are present in all biological ﬂuids
including blood plasma, synovial ﬂuid, cerebrospinal ﬂuid, urine, tears
and breast milk [1]. MPs are in between 100 and 1000 nm in diameter,
and they are also detectable by ﬂow cytometry [2,3]. Thus, MP proﬁles
are easily analyzed in the routine clinical laboratory practice, and repre-
sent novel biomarkers of various diseases. In circulation, most MPs are
derived from platelets, red blood cells, endothelial cells and leukocytes.
Because of their abundance, platelet-derived MPs (PMPs) received the
highest attention during the past few years. Elevated PMP counts are
characteristic for nearly all autoimmune disorders [4,5], and also for
several cardiovascular and metabolic diseases [1]. EVs not only contain
proteins but also RNA molecules [1]. Extracellular RNA (exRNA) in
blood plasma is encapsulated in EVs, or bound to either proteins or
HDL molecules [6]. exRNAs, particularly miRNAs, are speciﬁc and sensi-
tive biomarkers of various diseases (for a review see [7]).
Although MPs represent promising novel biomarkers, their
precise analysis is confounded by several pre-analytical factors
(e.g. blood sampling, transportation and centrifugation of blood [8,9])
and analytical issues [10]. Well-known confounding factors include i)
artiﬁcial, in vitro activation of platelets in the blood collection tube
induced by agitation or transportation [3], ii) residual platelets present
in „platelet-free plasma” [11], iii) detection threshold of the used
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ﬂow cytometer [2] and iv) presence of protein aggregates [12] or calci-
um phosphate microprecipitates [13] that mimic MPs during ﬂow cy-
tometry. Recently, in joint efforts supervised by the International
Society on Thrombosis and Haemostasis (ISTH), we and others sug-
gested standard pre-analytical and analytical procedures for the detec-
tion of MPs [2,3,10]. This will facilitate the improved ﬂow cytometry
measurement of these structures. However, there are remaining debat-
ed questions including the use of anticoagulants for MP analysis. Al-
though most studies used sodium-citrate tubes, some groups applied
ACD (acid-citrate-dextrose) tubes in their studies [14–16]. A recent re-
port by Jayachandran et al. suggested that neither citrate nor ACD tubes
were suitable for MP measurement as these anticoagulants may elimi-
nate MPs from plasma [17]. In contrast to the ISTH protocol, the above
authors suggested the use of heparin as an anticoagulant. Furthermore,
they proposed that published data on blood plasmaMP levels using so-
dium citrate or ACD as an anticoagulant may need re-evaluation [17].
This debate prompted us to carry out a systemic analysis on the effect
of anticoagulants on blood plasma MP levels. In this study we found
that ACD stabilizes MP count in the blood collection tube by inhibiting
in vitro vesiculation. Therefore we suggest the use of ACD tubes in
order to obtain a realistic picture of in vivoMP levelswithout interfering
with RNA analysis.
Materials and Methods
Blood Donors
We collected venous blood samples from healthy volunteers into
blood collection tubes containing different anticoagulants. The
donors did not take any medications in the last 3 months prior to
blood sampling, nor did they suffer from any chronic or acute disease
at the time of venipuncture. Smoking habit was documented. For the
comparison of different anticoagulants, we tested 30 healthy indi-
viduals (14 females, 16 males, mean age ± s.d.: 30.2 ± 11.0 years,
range: 22-59 years, 4 smokers). For these individuals, a routine blood
test was performed, and hemoglobin, platelet count, white blood cell
count, blood sugar, C-reactive protein, creatinine, gamma-glutamyl
transpeptidase, alanine aminotransferase and aspartate aminotransfer-
ase values were documented. These parameters were in the normal
range of all included subjects. To test the effect of citrate and ACD
tubes on artiﬁcially induced, in vitro vesiculation, we collected blood
plasma from further 6 healthy individuals (3 females, 3 males,
mean age ± s.d.: 24.8 ± 5.3 years, age range: 18-34 years, non-
smokers). To test the individual components of ACD (citric acid and
dextrose) on the inhibition of artiﬁcially induced vesiculation, we also
recruited 10 healthy individuals (7 women, 3 men, mean age ± s.d.:
38.8 years ± 10.5 years, age range: 23-53 years, all non-smokers).
Resistive pulse sensing experiments were carried out testing the
blood plasma of 3 individuals (2 women, 1 man, mean age ± s.d.:
33.0 ± 15.9 years). Furthermore, we collected blood plasma samples
from non-smoker pregnant women (6 women, mean age ± s.d.:
30.8 ± 1.3 years, range: 29-33 years, all in the third trimester), and 6
age matched healthy, non-pregnant, non-smoker women as controls
(mean age ± s.d.: 27.8 ± 5.2 years, range: 23-37 years). During the
entire investigation period, we followed the guidelines and regulations
of theHelsinki Declaration in 1975, and the experimentswere approved
by the Hungarian Scientiﬁc and Research Ethics Committee; all tested
individuals signed an informed consent form.
Blood Collection
During the entire investigation, we rigorously followed the
guidelines ISTH on blood sampling and handling for MP analysis
[3,9], except for the use of various blood collection tubes containing
different anticoagulants. In the present study we used tubes containing
citrate (sodium-citrate 3.2%, 3.5 ml volume, art. no.: 454332, Greiner
Bio-One, Frickenhausen, Germany), heparin (lithium-heparin, 3 ml
volume, art no.: 454244, Greiner Bio-One), EDTA (K3EDTA, 3 ml vol-
ume, art. no.: 454217), acid-citrate dextrose tube (ACD-A tube, 9 ml
volume, art. no.: 455055, Greiner Bio-One), citrate-theophylline-
adenosine-dipyridamole tube (CTAD, 3.5 ml volume, art. no.:
454462) and citrate phosphate dextrose adenine tube (CPDA, 6 ml
volume, art. no.: 456057). The venipuncture was performed in the
morning (8-11 hours am), while the donors were fasting. We used
a 21 Gauge needle for the venipuncture of an antecubital vein after
applying a light tourniquet. The ﬁrst few milliliters of blood were
discarded, and were not used subsequently for MP analysis. The
blood collection tubes were turned up and down ﬁve times gently
in order to mix anticoagulants with blood. The venipuncture was
performed within the same laboratory as blood sampling, thus, sam-
ples were not transported. The blood collection tubes were held in a
rack in an upright position until centrifugation at room temperature
(RT). During blood sampling and centrifugation the sequence of
order of tubes with different anticoagulants was randomized. The
centrifugation was performed within one hour after venipuncture.
The different anticoagulant tubes were handled exactly the same
manner by the same investigator.
Preparation of Platelet-Free Plasma (PFP)
We applied the ISTH protocol for preparation of PFP [3,9]. The blood
was centrifuged at 2,500 g at room temperature using a Hermle Z206A
table-top centrifuge (Hermle Labortechnik GmbH,Wehingen, Germany).
After 15 minutes of centrifugation, the platelet-poor plasma (PPP)
was aspirated. At least 500 μL of PPP was left in the tube in order to
minimize contamination with cells. The PPP samples were then
centrifuged once again at 2,500 g for 15 minutes. The PFP was then
collected (again, at least 100 μL was left in the polypropylene
tubes), aliquoted, snap frozen in liquid nitrogen, and stored at -80 °C de-
grees until analysis. Snap freezing of the samples did not result in any sig-
niﬁcant alteration in the MP count measured by ﬂow cytometry in the
case of citrate and ACD tubes (n = 9, Supplementary Fig. 1).
Flow Cytometric Analysis of PFP Samples
PFP samples were analyzed using a FACSCalibur ﬂow cytometer
(BD Biosciences, Franklin Lakes, NJ, USA). The ﬂow cytometry instru-
ment settings and MP gating were adopted from previous works
[2,12,16]. We used Megamix beads (BioCytex, Marseille, France) to
determine the gate for MPs, as described previously [2,18]. Brieﬂy,
0.5 μm, 0.9 μm and 3 μm beads were detected on an SSC/FL2 plot
(Supplementary Fig. 2A). Next, we selected bead regions, and back-
gated them on to the FSC/SSC plot (Supplementary Fig. 2B). MP
gate was set on the FSC/SSC plot as described previously [2,12,18]
(Supplementary Fig. 2B and C). Counting beads (3 μm in diameter,
Partec GmbH, Münster, Germany) were detected on the SSC/FL2
plot (Supplementary Fig. 2D). We applied our earlier protocol for
staining of MPs in biological ﬂuids [12]. Brieﬂy, 1 μg of anti-CD42a-
PerCP antibody (BD Biosciences) was added to 20 μL PFP, and incu-
bated for 30 minutes at RT in dark. The samples were then diluted
up to 400 μL in 0.9% sodium-chloride. Next, we added 2 μL of annexin
V-FITC (AX-FITC, BD Biosciences) to the samples. The amounts of AX-
FITC and anti-CD42a antibodies were determined in preliminary
tests. Before measurement, Ca2+ was added to the samples up to a
concentration of 2.5 mM, and samples were incubated for 5 minutes.
This calcium concentration resulted in maximal AX binding (as de-
termined in preliminary measurements), in accordance with previ-
ous works [19], except for EDTA tubes. EDTA is a strong chelator of
Ca2+, whose presence interferes with AX binding. Therefore we ex-
cluded EDTA samples from subsequent analysis in order to analyze
all samples at the same Ca2+ concentration. Event numbers of equal
sample volumes were counted for 60 seconds at medium ﬂow rate.
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Background ﬂuorescence was compared with that of the isotype-
control antibody. When detecting AX binding, 5 mM EDTA-containing
annexin-binding buffer solutionwas used to determine the background
ﬂuorescence. PMP (CD42+AX+) and non-PMP (CD42–AX+) counts
were enumerated (Supplementary Fig. 2E). They were referred to
known amounts of ﬂuorescent counting beads detected on the FL2
plot (Supplementary Fig. 2D). MP concentration was calculated using
the following formula: (MP concentration) = (MP count/bead count)
x bead concentration x plasma dilution. To verify if we detected MPs
(vesicular structures), and to exclude the presence of immune com-
plexes or protein aggregates, we added 0.1% Triton X-100 to the sam-
ples, as we described previously [5,12]. This step resulted in prompt
disappearance of ﬂuorescent event counts (Supplementary Fig. 2F) sug-
gesting the presence of membranous structures within the MP gate. All
measurements were carried out in NaCl solution instead of PBS in order
to avoid calcium microprecipitation [13].
Resistive Pulse Sensing
To test the size distributions and concentrations of MPs in blood
plasma anticoagulated with citrate or ACD, we performed resistive
pulse sensing analysis using a qNano instrument (Izon Science Ltd.,
Christchurch, New Zealand) [20]. The use of the 200 nm nanopore
membrane enabled us to cover the typical MP size range in the blood
plasma [12,21]. PFP samples were diluted 1:1 in 0.1 μm ﬁltered PBS.
This dilution was selected by previous serial dilution experiments test-
ing samples from undiluted ones to 1:1000 dilution. MPs were counted
for 5 minutes using 7.15 mbar pressure. Voltage was set in between
0.1-0.25 Volts in order to achieve a stable 100 nA current. Particle histo-
grams were recorded when RMS noise was below 12 pA, and particle
rate in time was linear.
Prothrombinase Assay
PFP samples were also analyzed by Zymuphen MP-Activity Kit
(Hyphen, BioMed, Neuville-sur-Oise, France), a functional assay of
the procoagulant activity of MPs. Brieﬂy, 1:20 diluted PFP samples
were applied onto plates coated with streptavidine and biotinylated
AX-V. After incubation at 37 °C for one hour, plates were washed 5
times with wash buffer provided by the manufacturer. Next, bovine
factor Xa–Va mixture and human prothrombin were added, and
plates were incubated for 10 minutes at 37 °C. After the addition of
the thrombin-speciﬁc chromogenic substrate, the reaction was stopped
with 2% citric acid, and absorbance was measured at 405 nm. Calibra-
tors were used, and values were expressed in phosphatidylserine (PS)
equivalents (nM PS).
Artiﬁcial Induction of In Vitro Vesiculation
We tested artiﬁcially induced release of MPs from platelets and
other cells in whole blood. We applied gentle, high frequency
(50 Hz), low amplitude shaking (similar to motor-vehicle transpor-
tation) using a plate shaker (Denley WeWarm1, Cat No.: WI-031,
DJB Labcare Ltd., Newport Pagnell, UK) for 1 hour at RT. We also tested
the effects of 1 hour incubation both at 37 °C and RT. As a control, we
measured PMP and non-PMP levels in PFP samples prepared immedi-
ately after blood sampling from the same donors.
Calibrated Automated Thrombogram
To analyze platelet function in citrate and ACD tubes, we used a
calibrated automated thrombogram (CAT) assay. Platelet rich plas-
ma (PRP) was prepared from blood plasma of 4 healthy individuals
(3 females, 1 male, mean age ± s.d.: 45.5 ± 11.7 years) using 180 g
centrifugation for 6 minutes. Platelet count was determined and plate-
let concentration was set to 150,000/μl by diluting the samples with
PFP. Reactionwas started bymixing 80 μl PRPwith 20 μl activator (con-
taining 1 pM tissue factor, Diagnostica Stago SAS, Nanterre, France) and
20 μl ﬂuorescent substrate (Diagnostica Stago), according to the manu-
facturer. Fluorescence was detected for 60 minutes using a Fluoroskan
Ascent CAT machine (Thermo Scientiﬁc, Waltham, MA, USA).
RNA Isolation and miRNA Analysis
To analyze miRNA content of plasma and blood plasma derived EVs,
we collected blood plasma samples into citrate and ACD tubes from 5
healthy donors (3 females, 2 males, mean age ± s.d.: 28 ± 3.7 years).
Total RNAwas isolated from 150 μl of PFP (ﬁltered through a 0.8 μm ﬁl-
ter) using Qiagen miRNeasy Mini Kit (Qiagen, Germantown, MD, USA).
We also isolated RNA from EVs isolated from the same PFP samples
(8 mL volume, these vesicle samples contained bothMPs and exosomes
in the 100,000 g for 60 minutes pellets) using Qiagen RNeasy Plus
Micro Kit (Qiagen). RNA quality was tested using RNA 6000 Pico Kits
(Agilent, Santa Clara, CA, USA) and small RNA fractions were deter-
mined using a small RNA kit (Agilent) on an Agilent 2100 Bioanalyzer.
In order to detect miRNAs both in PFP samples and EVs, we performed
real-time PCR assays for miR16, miR24, miR451 and let7a. Reverse tran-
scription of RNA was carried out using miRNA-speciﬁc stem-loop
primers (hsa-miR-16 [RT 391]; hsa-miR-24 [RT 402]; hsa-miR-451 [RT
1105]; hsa-let-7a [RT 377], Life Technologies, Carlsbad, CA, USA) and
TaqMan MicroRNA Reverse Transcription Kit (Life Technologies) on an
Applied Biosystems GeneAmp® PCR System 9700 machine. qPCR was
performed using SensiFAST™ Probe Hi-ROX One-Step Kit (Bioline,
Taunton, MA, USA) and miRNA-speciﬁc primers and probes (Life
Technologes) on an Applied Biosystems 7900HT Fast Real-Time PCR
machine. cDNA product was visualized by gel electrophoresis in 10%
polyacrylamide gels. We used a GeneRuler TM Ultra Low Range DNA
Ladder (0,5 μg/lane)(Thermo Scientiﬁc). For analysis, we used a
FluorChemTM 8000 Advanced Fluorescence machine (Alpha Innotech
Corporation, San Jose, CA, USA).
Statistical Analysis
We compared multiple groups using Kruskal-Wallis one way
analysis of variance on Ranks. Pairwise comparisons were carried
out using Signed Rank test. To compare two non-related sample
groups, we used Mann-Whitney Rank Sum test. For correlations,
we used Pearson product-moment correlation. For statistical testing,
we used the SigmaPlot for Windows, version 11.0 (Systat Software,
Inc., San Jose CA, USA).
Results
Comparison ofMP Counts in Different Anticoagulant Blood Collection Tubes
First we enumerated PMPs (CD42+AX+ MPs) and non-PMPs
(CD42–AX+ MPs) by ﬂow cytometry in PFP samples collected into
tubes with different anticoagulants (Fig. 1A and B). The PMP concen-
tration in the citrate plasma sampleswas around 102-104/μl in our study
(median (1st quartile to 3rd quartile): 1,152/μl (251/μl-4,553/μl)), con-
sistent with previous ﬁndings [10]. The type of anticoagulant signiﬁ-
cantly inﬂuenced both the PMP and non-PMP levels (p = 0.002 for
PMPs and p b 0.001 for non-PMPs, Kruskal-Wallis one way analysis
of variance on Ranks). The highest PMP and non-PMP counts were
found in heparin tubes, and differed signiﬁcantly from PMP and
non-PMP counts in citrate tubes (p = 0.012 and p b 0.001, respective-
ly, Signed Rank test). The citrate, CTAD and CPDA tubes contained near-
ly equal amounts of MPs. The lowest MP count was detected in ACD
tubes. The PMP count in this tube differed signiﬁcantly from that of cit-
rate tube (p = 0.04, Signed Rank test). Furthermore, inter-individual
differences (reﬂected by standard deviation) of healthy samples
were also the lowest in the case of the ACD tube samples. Using the
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Zymuphen assay, we obtained similar results (Fig. 1C). The median
(1st quartile to 3rd quartile) PS concentration was 7.4 nM (4.7-
10.1 nM) in the citrate samples, which was consistent with the
healthy range determined by the manufacturer. Similarly to ﬂow
cytometry results, the plasma samples in heparin tubes showed
the highest PS concentration (however, the difference was not signiﬁ-
cant compared to citrate tubes). On the contrary, ACD, CTAD, CPDA
tubes contained signiﬁcantly less PS as compared to citrate tubes
(p = 0.017, p = 0.003 and p = 0.006, respectively, Signed Rank test).
Next we assessed if there was a correlation between ﬂow cytometry
and Zymuphen assay results (Supplementary Fig. 3). Zymuphen assay
detects all PS positive structures including small MPs and exosomes in-
visible for many ﬂow cytometers. We analyzed the correlation between
all AX+ MPs detected by ﬂow cytometry (the sum of PMPs and non-
PMPs) and Zymuphen assay results. Therewas only a tendency between
the twomethods in the case of citrate tubes (R = 0.385, Pearson corre-
lation), and therewas no correlation in the case of CPDA, CTAD and hep-
arin tubes. Of note, there was a correlation in the case of ACD tubes
(R = 0.794, p = 0.00005, Pearson correlation).
The lowest MP numbers and lowest standard deviation detected
in the ACD tubes might indicate that artiﬁcial, in vitro vesiculation
is limited in ACD tubes, compared to other tubes. Based on these
ﬁndings we selected ACD tube as a candidate optimal anticoagulant,
and in the rest of this study, we compared artiﬁcial in vitro vesicula-
tion in ACD tube and citrate tubes (the latter being suggested by the
latest ISTH recommendation [3]).
Artiﬁcially Induced Vesiculation in Citrate and ACD Tubes
We induced in vitro release ofMPs inwhole blood by gentle agitation
and incubation of the blood samples at various temperatures. In ac-
cordance with previous reports [9], agitation of whole blood in
citrated tubes resulted in a dramatic, however, highly variable increase
(3-29 fold) of both PMP and non-PMP counts compared to untreated
controls (Fig. 2A and B) (p = 0.03 and p = 0.03, respectively, Signed
Rank test), measured by ﬂow cytometry.
Similarly, incubation for one hour at 37 °C resulted in 2-3 fold
elevation of PMP and non-PMP counts in citrate tubes (p = 0.03
and p = 0.03, respectively, Signed Rank test). Strikingly, in ACD tubes,
handled exactly the samemanner as citrate tubes, there was only mod-
erate, non signiﬁcant elevation of PMPs and non-PMPs both after gentle
agitation and 37 °C incubation (Fig. 2A and B). The incubation of whole
blood at RT for one hour did not result in signiﬁcant changes in MP
levels either in the case of citrate or ACD tubes. Using the Zymuphen
assay, we observed similar results: in plasma samples from citrate
tubes, PS concentration was elevated after agitation and 37 °C incuba-
tion (n = 3) (Fig. 2C). Similarly, one hour incubation at RT also resulted
in an average of 5-fold elevation in PFP samples in citrate tubes. Most
importantly, in ACD tubes, PS concentration remained unchanged
after both agitation and incubation either at 37 °C or RT (Fig. 2C).
These data strongly support that in ACD tubes, artiﬁcially induced
(in vitro) vesiculation of blood cells is successfully prevented.
The Effect of Citric Acid and Dextrose on Artiﬁcially Induced Vesiculation
To investigate which component of the ACD tubes was responsible
for the inhibition of in vitro vesiculation, we analyzed the effect of citric
acid anddextrose. These substanceswere added separately to the blood,
drawn into conventional citrate tubes up to a concentration characteris-
tic for the commercial ACD tube (8 g/L citric acid and 24.5 g/L dextrose).
Then, the tubes were subjected to gentle agitation or 37 °C 1 hour incu-
bation, as described above. The addition of citrate successfully inhibited
the release of PMPs during both agitation and 37 °C incubation (Signed
Rank test, p = 0.01 and p = 0.016, respectively) (Fig. 3A). The forma-
tion of non-PMP countswas also inhibited by citric acid during 37 °C in-
cubation (p = 0.016), but the release of PMPs was not inhibited during
shaking (Fig. 3B). Dextrose alone could not inhibit the formation of ei-
ther PMPs or non-PMPs counts during any of the tested conditions
(Fig. 3A and B).
These data suggest that the active component of ACD tubes that
inhibits artiﬁcial in vitro vesiculation, is citric acid which decreases
the pH of the blood sample to approximately 6.0 [22].
To conﬁrm that platelets are inhibited in ACD tubes (that do not con-
tain direct platelet inhibitors), we performed CAT measurement of PRP
samples in citrate or ACD tubes. Clearly, there was a signiﬁcant delay in
the activation of platelets, the velocity of activation was smaller and the
Fig. 1. Comparison of the effect of different anticoagulants on theMP countsmeasured byﬂow cytometry and Zymuphen assay. PMP (CD42a+AX+) (a) and non-PMP (CD42a-AX+)
(b) counts enumerated by ﬂow cytometry, (c) results of Zymuphen assay. Horizontal lines represent mean values. *p b 0.05, **p b 0.01, ***p b 0.001, n = 30.
Fig. 2. The effect of citrate or ACD on the in vitro release ofMPs. Counts of PMPs (a) and non-PMPs (b)measured by ﬂow cytometry, and Zymuphen assay (c). The y axis represents fold
increase compared to PFP samples isolated immediately after blood sampling. RT denotes room temperature.Mean ± s.d. values are shown. *p b 0.05 compared to untreated control sam-
ples (Signed Rank test), n = 6.
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amount of total thrombin activity was also impaired in tubes with ACD
(Supplementary Fig. 4). These results indicate that platelet inhibition
explains the fewer numbers of PMPs in the PFP samples fromACD tubes.
Detection of Pregnancy Related Elevation of PMP and non-PMP Counts is
not Confounded in ACD Tubes
Next, we assessed if the MP count elevated in vivowas also detect-
able in ACD tubes in pregnancy (a condition where elevated levels of
PMPs and non-PMPs were reported previously in citrate tubes [23]). In-
deed, there was a signiﬁcant elevation in the PMP and non-PMP counts
in pregnant women compared to non-pregnant healthy controls in cit-
rate tubes (p = 0.002 and p = 0.004, respectively, Mann-Whitney
Rank Sum test) (Fig. 4). Importantly, the pregnancy-related elevation
was also detectable in ACD tubes (p = 0.015 for PMPs and p = 0.002
for non-PMPs, Mann-Whitney Rank Sum test) (Fig. 4).
Size Distribution of MPs in Citrate and ACD Tubes
Using the qNano instrument, we determined the size distribu-
tions of blood plasma MPs in both citrate and ACD tubes (Fig. 5).
We did not detect any signiﬁcant difference between the vesicle
sizes in the two types of anticoagulant tubes. The mean (±s.d.) di-
ameter of particles was 242.3 nm (±5.8) nm in the case of citrate
tubes and 230.8 (±9.2) nm in the case of ACD tubes. Concentration of
particles was lower in ACD tubes (Fig. 5) as compared to those in citrate
tubes (in accordance with data obtained by ﬂow cytometry and
Zymuphen assay).
RNA Analysis of Blood Plasma and EVs from Citrate and ACD Tubes
Based on the above data, we propose the use of ACD tubes for the
assessment of circulating MPs. Recently, several studies analyzed
exRNA content of vesicles or blood plasma (or serum) [24,25]. We
tested ACD tubes for downstream RNA analysis. Blood plasma and
total EV (including both exosomes and MPs in the pellets) RNA pro-
ﬁles were similar between conventional citrate and ACD tubes (Sup-
plementary Fig. 5A). We detected almost exclusively small RNA
molecules in all samples, 18S and 28S RNAs were absent. We next
applied small RNA analysis to determine the percentage of miRNAs
in EV samples. We found that 46.8 ± 0.8% (175.1 ± 51.9 pg/μL)
and 45.2 ± 2.3% (164.3 ± 77.1 pg/μL) of small RNAs were miRNAs
Fig. 3. The effect of ACD components on the in vitro release of PMPs (a) and non-PMPs (b) determined by ﬂow cytometry. Citric acid or dextrose was added separately to the tubes,
and blood samples were subsequently subjected to agitation or 1 hour incubation at 37 °C. Mean ± s.d. values are shown. *p b 0.05, n = 10.
Fig. 4. MP counts in pregnancy measured in citrate and ACD tubes determined by ﬂow cytometry.Mean ± s.d. values are shown. *p b 0.05, ** p b 0.01, n = 6 in each group.
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in citrate and ACD tubes, respectively. To further conﬁrm the presence
of miRNAs in the samples, we performed qRT-PCR analysis speciﬁc for
miR16, miR24, miR451 and let7a. The presence of these miRNAs in
blood or in vesicles has been conﬁrmed earlier [24,25]. We found that
all analyzed miRNAs were detectable in EVs and in blood plasma,
both in the case of citrate and ACD tubes (Supplementary Fig. 5B).
There was no signiﬁcant difference in CT values for the above ana-
lyzed miRNAs between ACD and citrate tubes (equal amount of plas-
ma was used for vesicle isolation or for RNA isolation).
Discussion
In this systemic study, we assessed whether the use of various
anticoagulants affected the measured MP counts and in vitro vesicu-
lation of blood cells. Indeed, we found that MP levels, determined by
ﬂow cytometry and Zymuphen assay, were signiﬁcantly different in
tubes with various anticoagulants. In accordance with previous results,
the highest MP count was detected in tubes with heparin, and the low-
est was found in ACD tubes [17]. This may be due to the fact that unlike
other anticoagulants used in this study, heparin is not a calcium che-
lator, and calcium is known to play a crucial role in vesiculation
[26,27]. We demonstrated that the use of citrate, a weak chelator of
calcium, resulted in a signiﬁcantly reduced number of MPs compared
to heparin in the blood collection tube. Interestingly, we found com-
parable levels of PMP and non-PMP counts. This is in contrast with
previous ﬁndings [1], as most previous works found PMPs the main
MP population in blood plasma. However, many of these earlier
works did not control for the presence of residual platelets, and did
not use pre-analytical parameters suggested by the ISTH [3]. Thus,
many of these vesicles might have corresponded to in vitro formed
MPs. Recent standard protocols [3] use very efﬁcient centrifugation
and rigorous pre-analytical settings in order to remove most of
platelets, resulting in lower number of PMPs.
In Zymuphen assay, tubes containing platelet inhibitors (CTAD,
CPDA and ACD) showed decreased MP counts. In this assay, citrate
tubes gave comparable results to heparin in contrast to data obtained
by ﬂow cytometry. This controversy may be explained by the fact
that Zymuphen assay does not only detect all types of AX+ EVs
(even exosomes), but also any PS positive cells that may possibly re-
main in the PFP samples [11]. In contrast, during ﬂow cytometry we
gated on the MV size range only, and smaller or larger particles were
thus, excluded from detection. By using the resistive pulse sensing
approach, we detected much higher number of events than by ﬂow
cytometry. This is in accordance with previous reports [20], and is
explained by the fact that ﬂow cytometry is able to detect events
above 200-300 nm, while the threshold for qNano detection is
lower. Furthermore, van der Pol et al. reported the presence of mul-
tiple vesicles in the laser beam (swarm effect) that was responsible
for an up to 1000-fold underestimation of MPs by ﬂow cytometry
[20].
Next, we focused on ACD and citrate tubes. Apparently, every single
step from blood sampling to analysis may affect MP counts [8]. It has
been shown previously that intense agitation of the tubes results in a
strong elevation in MP count, and a signiﬁcant decrease in the clotting
time [9]. Furthermore, unsupported transportation and a delay between
blood collection and the ﬁrst centrifugation of samples also resulted in a
signiﬁcant increase in MP counts [9]. In the present study, we applied a
high frequency and low amplitude gentle agitation, which induced an
increase of PMP counts in citrate but not in ACD tubes.We also assessed
the effect of blood sample storage at 37 °C which increased both PMP
and non-PMP counts in citrate tubes but not in ACD ones. Our results in-
dicate that in vitro platelet vesiculation is prevented in ACD tubes com-
pared to the commonly used citrate tubes. Most interestingly, tubes
containing direct platelet inhibitors, like theophylline, adenosine and
dipyridamole (CTAD tubes) could not inhibit in vitro vesiculation. ACD
tubes contain dextrose and citric acid, which components were sep-
arately analyzed in our work. Dextrose had no effect on the counts of
vesicles. Both in the case of PMPs and non-PMPs, citric acid was
found responsible for the inhibition of vesiculation. The ACD tube was
reported to result in pH 6.0 value of the blood sample [22]. The authors
reported that platelets prepared in ACD tubes, showed signiﬁcantly
fewer signs of activation compared to platelets in sodium-citrate tubes.
Platelets retained their resting discoid morphology in ACD tubes, and
the expression of the activation marker GPIIb-IIIa was also inhibited
[22].
The inhibitory activity of local acidosis on platelets has been
described long time ago [28]. Low pH was shown to inhibit ADP-
induced change in platelet shape, adhesion, spreading and interaction
with ﬁbrinogen, ﬁbronectin or collagen [29]. The mechanism is likely
due to inhibition of the store-operated calcium inﬂux into platelets in
extracellular acidosis [30]. Lower intracellular calcium concentration
results in the inhibition of haemostatic functions of platelets. As calcium
Fig. 5. Particle size distributions measured by resistive pulse sensing (qNano). Histograms show a representative PFP sample (diluted 1:1 in PBS), n = 3.
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is known to be required for vesiculation [26,27], it is not surprising that
in vitro vesiculation was successfully dampened in the acidic envi-
ronment. In this study, using CAT we also conﬁrmed that platelets
are markedly inhibited in ACD tubes. This inhibition might explain
why PMP levels were generally lower in these tubes and why fur-
ther effects related to blood handling failed to induce in vitro vesi-
cle formation from platelets. However, a direct link between
extracellular acidosis and vesiculation is yet to be established, and
the inhibition of blood cells other than platelets in ACD tubes is
yet to be conﬁrmed.
Taken together, ACD tubes appear more suitable for MP analysis
than any other types of anticoagulant tubes as they inhibit in vitro
vesiculation. Importantly, detection of in vivo elevated MP counts
was not prevented in ACD tubes.
Based on our data, if sufﬁcient care is taken to handle blood tubes,
if samples are centrifuged shortly after blood sample collection and
benchtop storage temperature is at around RT, both citrate and
ACD tubes give comparable results.
In the past couple of years, hundreds of articles assessed MPs
from blood plasma using ﬂow cytometry. The data, particularly on
PMP counts, are often controversial; some studies show elevated
levels of PMPs in a given condition, while some others fail to show
an association (e.g. venous thromboembolism, [31]) One possible
explanation for these results is the in vitro vesiculation of blood
cells induced by many physical factors.
RNA proﬁles were found similar in citrate and ACD tubes. Mostly
small RNAs were detected, and detailed Bioanalyzer analysis revealed
that small RNA fractions contained miRNA in high amounts. The
presence of miR16, miR24, miR451 and let7a in plasma has already
been described [24,25], and we found no difference in the quantity
of these RNAs in citrate and ACD tubes. Thus, as there was no differ-
ence in citrate and ACD tubes in terms of exRNA proﬁles and quanti-
ties of the studied speciﬁc miRNAs, ACD tubes are not only suitable
for protein analysis of MVs, but also for exRNA extraction and subse-
quent analysis.
Taken together, we suggest the use of ACD tubes for clinical lab-
oratory assessments of MP counts because in practice a strict con-
trol of transportation, temperature and delay between sample
collection and analysis, is not always feasible. Conclusively, sample
collection in ACD tubes may represent an important step towards
standardization of both fresh and biobanked plasma samples for
MP studies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.thromres.2013.11.010.
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